1. Home
  2. KINS vs FATE Comparison

KINS vs FATE Comparison

Compare KINS & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

N/A

Current Price

$22.93

Market Cap

279.5M

Sector

Finance

ML Signal

N/A

Logo Fate Therapeutics Inc.

FATE

Fate Therapeutics Inc.

N/A

Current Price

$1.30

Market Cap

260.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KINS
FATE
Founded
1886
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
279.5M
260.0M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
KINS
FATE
Price
$22.93
$1.30
Analyst Decision
Buy
Analyst Count
0
11
Target Price
N/A
★ $5.72
AVG Volume (30 Days)
93.7K
★ 1.5M
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 1.03%
N/A
EPS Growth
★ 94.59
29.88
EPS
★ 1.86
N/A
Revenue
★ $214,867,301.00
$6,646,000.00
Revenue This Year
$18.83
N/A
Revenue Next Year
$15.85
$18.72
P/E Ratio
$12.49
★ N/A
Revenue Growth
★ 38.50
N/A
52 Week Low
$13.83
$0.95
52 Week High
$23.42
$3.23

Technical Indicators

Market Signals
Indicator
KINS
FATE
Relative Strength Index (RSI) 67.82 23.18
Support Level $18.35 $1.07
Resistance Level N/A $1.38
Average True Range (ATR) 0.86 0.16
MACD 0.33 -0.07
Stochastic Oscillator 86.05 7.35

Price Performance

Historical Comparison
KINS
FATE

About KINS Kingstone Companies Inc.

Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.

About FATE Fate Therapeutics Inc.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Share on Social Networks: